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ABSTRACT
Background Previous studies have suggested that 
some medications may influence dementia risk. We 
conducted a hypothesis- generating medication- wide 
association study to investigate systematically the 
association between all prescription medications and 
incident dementia.
Methods We used a population- based cohort within 
the Secure Anonymised Information Linkage (SAIL) 
databank, comprising routinely- collected primary care, 
hospital admissions and mortality data from Wales, 
UK. We included all participants born after 1910 and 
registered with a SAIL general practice at ≤60 years old. 
Follow- up was from each participant’s 60th birthday to 
the earliest of dementia diagnosis, deregistration from 
a SAIL general practice, death or the end of 2018. We 
considered participants exposed to a medication if they 
received ≥1 prescription for any of 744 medications 
before or during follow- up. We adjusted for sex, 
smoking and socioeconomic status. The outcome was 
any all- cause dementia code in primary care, hospital or 
mortality data during follow- up. We used Cox regression 
to calculate hazard ratios and Bonferroni- corrected p 
values.
Results Of 551 344 participants, 16 998 (3%) 
developed dementia (median follow- up was 17 years 
for people who developed dementia, 10 years for those 
without dementia). Of 744 medications, 221 (30%) were 
associated with dementia. Of these, 217 (98%) were 
associated with increased dementia incidence, many 
clustering around certain indications. Four medications 
(all vaccines) were associated with a lower dementia 
incidence.
Conclusions Almost a third of medications were 
associated with dementia. The clustering of many drugs 
around certain indications may provide insights into 
early manifestations of dementia. We encourage further 
investigation of hypotheses generated by these results.
INTRODUCTION
Dementia is a major global health challenge.1 There 
were an estimated 47 million people living with 
dementia in 2015, and the global prevalence is 
estimated to rise to 131 million by 2050.2 In the 
absence of disease- modifying therapies, prevention 
of dementia by addressing modifiable risk factors is 
a key goal.3 Recent studies have suggested that some 
medications, such as anticonvulsants4 and anticho-
linergic drugs,5 6 may be associated with increased 
risk of dementia, raising the possibility that avoiding 
these medications could reduce dementia incidence. 
The availability of large, population- based health-
care datasets, coupled with increasing computa-
tional capacity, provides the opportunity to explore 
systematically the association between medications 
and diseases, enabling the discovery of previously 
unknown associations and reducing the likelihood 
of selective analysis and reporting.7
Environment- wide association studies (EWAS) 
were developed to be analogous to genome- wide 
association studies, allowing a hypothesis- free 
approach to discovering new environmental risk 
factors or predictors of disease, while minimising 
reporting bias and controlling for the rate of false 
positives.8 9 Medication- wide association studies, a 
type of EWAS in which only medications are eval-
uated, provide a hypothesis- generating approach 
to studying the relationship between drugs and 
disease.7 10
We used a population- based, electronic cohort 
(e- cohort) to conduct a hypothesis- generating 
medication- wide association study to investigate 
the association between prescription drugs and 
dementia during the follow- up period.
METHODS
Study design
We conducted a medication- wide association study 
using a population- based, retrospective cohort 
composed from routinely- collected healthcare data.
Datasets
The Secure Anonymised Information Linkage 
databank (SAIL) contains individual- level, linked 
routinely- collected healthcare datasets for the 
population of Wales, UK. Currently, SAIL includes 
primary care data for approximately 80% of the 
population of Wales. Included participants are 
representative of the entire Welsh population with 
regards to age, sex and deprivation.11 The SAIL 
Dementia e- cohort (SAIL- DeC) consists of derived 
variables from coded, linked primary care, hospital 
admissions, mortality and deprivation datasets 
for a large subset of SAIL participants. In the UK, 
diagnoses within hospital admissions and mortality 
data are coded using the International Classifi-
cation of Diseases version 10 (ICD-10) system.12 
Primary care data in Wales are coded using the Read 
Version 2 (Read V2) system.13 14 The creation of the 
SAIL- DeC resource is outlined in detail elsewhere.11 
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the SAIL Databank who were born between 1 January 1900 and 
1 January 1958 and for whom primary care data are available 
(n=1.2 million). The cohort data dictionary and ICD-10 and 
Read V2 code lists used to derive the variables within SAIL- DeC 
are available at https://datashareedacuk/handle/10283/3268. 
This study was approved by the SAIL Information Governance 
Review Panel (application number 0837), which includes repre-
sentatives from the Research Ethics Service and the public. Partic-
ipants can opt- out of having their anonymised data provided to 
SAIL by making an enquiry to the relevant data provider.
Study population and follow-up
We included all SAIL- DeC participants born after 1910 and first 
registered with a SAIL general practice when aged ≤60 years. 
We excluded anyone with a dementia code in primary care, 
hospital admissions or mortality data before their 60th birthday 
and those with missing month and year of birth or deprivation 
fields (figure 1). Follow- up for all participants started on the 
week of their 60th birthday and ended at the earliest of dementia 
diagnosis, end of registration with a SAIL general practice, death 
or end of 2018.
Exposures
Prescription information in SAIL is contained within the five- 
byte Read V2- coded primary care data. The first three digits of 
the code define the drug name, with the remaining two digits 
describing the strength and formulation. The Read V2 system 
maps directly onto the hierarchical system within the British 
National Formulary (BNF, table 1).15 The BNF contains infor-
mation on the indications, contraindications, side effects and 
doses for prescription medications in the UK. We grouped the 
medications data into 2626 drugs, based on the first three digits 
of the Read code (online supplemental material).
We included any drug that was prescribed to ≥1000 study 
participants. Participants were considered ‘exposed’ to a drug 
from the date of a first prescription for that medication, or from 
the study start date for that participant (the week of their 60th 
birthday) if the first prescription occurred before the age of 
60. We excluded any prescriptions from the analysis that first 
appeared in the month before a participant’s dementia diagnosis.
Outcome
The outcome was defined as the first all- cause dementia code 
in any of primary care, hospital admissions or mortality data-
sets, using a validated code list (online supplemental material).16 
For patients who also received a prescription for a drug used to 
treat dementia (donepezil, rivastigmine, galantamine or meman-
tine), the date of dementia diagnosis was taken as the earliest 
of the date of first prescription of that drug or the date of the 
first dementia code in any dataset. We excluded patients with a 
dementia drug code but no diagnostic code from the analysis, 
due to uncertainty about whether they represented cases or 
non- cases.
Statistical analysis
We derived descriptive statistics for the study population, subdi-
vided into those who developed dementia during follow- up 
(cases) or not (non- cases).
We divided the study population into derivation and valida-
tion cohorts (1:1 random allocation based on 1909 geographical 
household areas (Lower Layer Super Output Areas)). We used a 
Cox proportional hazards model, with age used as the time vari-
able. We adjusted for sex, socioeconomic status (quintiles) and 
Figure 1 Study flow diagram. Categories are not mutually exclusive. 
*Confidence in linkage to any routinely- collected dataset <95%. 
GP, general practice; SAIL, Secure Anonymised Information Linkage 
databank.
Table 1 British National Formulary (BNF) chapters and corresponding 
Read V2 codes
BNF chapter Category Read code
1 Gastrointestinal system a….
2 Cardiovascular system b….
3 Respiratory system c….
4 Central nervous system d….
5 Infections e….
6 Endocrine system f….
7 Obstetrics, gynaecology and urinary- tract disorders g….
8 Malignant disease and immunosuppression h….
9 Nutrition and blood i….
10 Musculoskeletal and joint diseases j….
11 Eye k….
12 Ear, nose and oropharynx l….
13 Skin m….
14 Immunological products and vaccines n….
15 Anaesthesia o….
The BNF is divided into chapters, each consisting of multiple sections. Read drug codes 
(version 2) are five digits, with the first letter indicating the corresponding BNF chapter. 
Medications in chapter 15 (anaesthesia) were not included in this study, as these drugs 
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smoking status (ever- vs never- smokers). Covariate definitions 
are outlined in detail in the SAIL- DeC cohort profile.11
There is no single established method of adjusting for multiple 
testing in EWAS analyses,7–9 with a balance needing to be 
struck between minimising type I error (false positive results) 
and avoiding very large type II error (false negative results). 
We therefore employed two different methods. First, we used 
a Bonferroni correction (0.05 divided by number of drugs 
studied) in both the derivation and validation datasets, referring 
to any medications that passed this stringent threshold in each 
dataset as being ‘associated’ with dementia. Second, we used 
the Benjamini- Hochberg procedure in the derivation dataset to 
establish a False Discovery Rate (FDR) of 10%. For any medi-
cations passing this FDR threshold, we used a further threshold 
of p<0.05 in the validation dataset, referring to medications 
passing this as being ‘tentatively associated’ with dementia. For 
the purposes of reporting, we then combined the derivation and 
validation cohorts to produce hazard ratios (HRs) and p values 
for all medications.
We also conducted sensitivity analyses, using Alzheimer’s 
disease subtype codes (rather than all- cause dementia) as the 
outcome, and, to investigate the potential for reverse causation, 
only including medications prescribed for the first time ≥5 or 
≥10 years before dementia diagnosis. For each, we plotted the 
log HR from the sensitivity analysis against the original log HR.
We conducted statistical analyses using R ( www. r- project. org).
Evaluating the results
One reason a medication may be associated with dementia is 
because it is prescribed for a condition that is itself associated 
with dementia (confounding by indication). Two clinicians (TW 
and KB) screened all associated medications, highlighting those 
that are commonly prescribed in one of five situations (‘Group 
1’): neurodegenerative diseases, cardiovascular disease, diabetes, 
depression and symptoms or complications of dementia (eg, 
antipsychotics or nutritional supplements). This list was not 
designed to include all conditions that are associated with 
dementia, but rather to provide a framework to aid interpreta-
tion and reporting of the results.
For each of the remaining associated medications (‘Group 2’), 
we compared the HRs to those of all other drugs within the 
same BNF section to look for patterns and generate hypotheses. 
We considered whether HRs of medications in the same section 
were similar, even if small sample sizes precluded some from 
meeting the threshold for significance.
RESULTS
Study characteristics
A total of 551 344 participants met the eligibility criteria 
(figure 1), resulting in 5 826 209 person- years of follow- up. 
Of these, 16 998 (3.1%) developed dementia during follow- up. 
Median follow- up time was 17.0 years for those who developed 
dementia and 9.7 years for those who did not receive a dementia 
diagnosis. Characteristics of the study population are shown in 
table 2.
All medications
A total of 744 (28%) medications were included in the anal-
ysis. With Bonferroni correction, 245 medications passed the 
threshold of significance in the derivation dataset. Of these, 
24 did not meet the significance threshold in the validation 
dataset, leaving 221 (29.7%) medications ‘associated’ with 
dementia (figure 2). A further 100 medications were ‘tentatively 
associated’. Of the 221 medications associated with dementia, 
217 (98%) were associated with a higher dementia incidence. 
Only four (2%) medications (all vaccines) were associated 
with a lower dementia incidence. The full results table for all 
744 medications included in the analysis is available at https:// 
datashare. ed. ac. uk/ handle/ 10283/ 3792. From the 221 medica-
tions associated with dementia, 107 were indicated for one of 
the five situations where we predicted a priori that there could 
be confounding by indication (Group 1), leaving 114 medica-
tions in Group 2.





Not diagnosed with 
dementia*
Total participants 16 998 534 346
Female (%) 8903 (52) 267 340 (50)
Total follow- up time (person- years) 279 720 5 546 489
Median follow- up time (years) 17.0 9.7
Median year at start of follow- up† 1998 2007
Deprivation quintile (%)
  1 – Most deprived 3769 (22) 95 381 (18)
  2 3106 (18) 98 448 (18)
  3 3348 (20) 113 807 (21)
  4 3048 (18) 105 032 (20)
  5 – Least deprived 3727 (22) 121 678 (23)
Polypharmacy (%) 2602 (15) 79 801 (15)
Ever smoker (%) 12 207 (72) 353 090 (66)
*Did not develop dementia by the end of follow- up. Smoking was defined as being an 
ever- versus never- smoker. Polypharmacy was defined as being prescribed ≥10 different 
drugs during the first year of the observation period (from age 60–61 years).
†Median year at age 60 years. 
Figure 2 Volcano plot demonstrating the hazard ratio (HR) and 
p value for the association between all medications and incident 
dementia. Each marker represents a single medication. Grey markers 
represent medications that did not pass the Bonferroni- corrected 
threshold of significance in both derivation and validation cohorts. 
Coloured markers represent medications that were found to be 
significantly associated with dementia. Each colour represents a 
different British National Formulary section. HRs are on a log scale and 
are from the entire study population (derivation and validation cohorts 
combined). All markers above the upper horizontal dotted line had p 
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Group 1: Medications expected a priori to be associated with 
dementia
Many medications indicated for neurodegenerative diseases, 
cardiovascular disease, diabetes, depression and symptoms 
or complications of dementia were associated with dementia 
(online supplemental material).
Group 2: Medications expected a priori to be associated with 
dementia
BNF chapter 1: Gastrointestinal system
1.1 Dyspepsia and gastro-oesophageal reflux disease
Magnesium salts, ‘compound proprietary antacids D- L’ and 
‘compound proprietary antacids M- Z’ were all associated with 
dementia (HR range 1.22–1.63). Other drugs within this BNF 
section had similar HRs (HR range 1.14–1.51), suggesting a 
similar effect size, but with smaller numbers of exposed dementia 
cases.
1.3 Antisecretory drugs and mucosal protectants
Ranitidine (H2 antagonist), omeprazole and lansoprazole 
(proton pump inhibitors) were all associated with dementia with 
similar HRs (HR range 1.19–1.21), while pantoprazole was 
tentatively associated with a similar effect size (HR 1.20).
1.4 Acute diarrhoea
Loperamide was associated with dementia (HR 1.42), while the 
other drugs in this section were tentatively associated (diphenox-
ylate hydrochloride: HR 1.27; codeine phosphate for gastroin-
testinal tract use: HR 1.34).
1.5 Laxatives
Almost all medications in this section were associated with 
dementia (HRs 1.39–2.27).
BNF chapter 4: Central nervous system
4.1 Hypnotics and anxiolytics
All but one medication in this section were either associated or 
tentatively associated with dementia. HRs ranged from 1.27 
(hydroxyzine) to 3.37 (lorazepam). In addition to benzodiaz-
epines, other drugs for insomnia (eg, zopiclone, zolpidem and 
melatonin) were associated with dementia.
4.6 Drugs used in nausea and vertigo
All medications in this section were associated with dementia 
(HR range 1.20–2.88), except ondansetron which had a similar 
HR (1.44) but only small numbers of exposed dementia cases.
4.7 Analgesics
Apart from drugs indicated for migraine, almost all medica-
tions in this section were associated or tentatively associated 
with dementia (HR range 1.22–1.89). Most were opiate drugs, 
although medications with alternative mechanisms of action 
such as paracetamol and nefopam were also associated or tenta-
tively associated.
4.8 Antiepileptic drugs
All anticonvulsant drugs were associated with dementia, apart 
from topiramate which was tentatively associated. Effect sizes 
were generally large (HR range 1.53–4.99).
4.10 Drugs used in substance dependence
Acamprosate calcium, used to treat alcohol dependence, was 
associated with dementia with a large effect size (HR 4.15). 
Nicotine replacement therapies were associated or tentatively 
associated with dementia (HR range 1.31–1.37). Bupropion and 
varenicline, used as smoking cessation aids, were not associated.
BNF chapter 5: Infections
5.4 Antimalarials
Quinine, originally an antimalarial but much more widely used 
for leg cramps, was associated with a higher dementia risk (HR 
1.23). By contrast, mefloquine hydrochloride and ‘atovaquone 
and proguanil hydrochloride’ were tentatively associated with 
a lower likelihood of developing dementia (HR range 0.60–
0.63). Other antimalarials also had HRs <1, but with few cases 
exposed.
BNF chapter 7: Obstetrics, gynaecology and urinary-tract disorders
7.4 Drugs for genito-urinary disorders
Tamsulosin, oxybutynin, tolterodine L- tartrate, trospium chlo-
ride, solifenacin, duloxetine and ‘catheter patency solutions’ 
were all associated with dementia (HR range 1.38–3.44), while 
flavoxate hydrochloride, fesoterodine fumarate and mirabegron 
were tentatively associated (HR range 1.71–2.15). Only tadalafil 
was tentatively associated with lower dementia incidence (HR 
0.87). Of note, many of the drugs in this section have anticholin-
ergic activity, but those without, such as mirabegron, tamsulosin 
and ‘catheter patency solutions’ also had HRs >1.
BNF chapter 14: Vaccines and antisera
Four vaccines were associated with a lower risk of dementia: 
hepatitis A (HR 0.78), typhoid (HR 0.80), hepatitis A and 
typhoid combined (HR 0.68), and diphtheria (HR 0.79). Vari-
cella zoster vaccine was tentatively associated (HR 0.73). The 
influenza vaccine, which is routinely offered to patients with 
chronic health conditions and all people ≥65 years of age in the 
UK, was the only vaccine associated with a higher dementia risk 
(HR 1.11).
Sensitivity analyses
In general, when participants who first received a drug <5 
and<10 years before a dementia diagnosis were excluded, HRs 
were lower (figure 3). Of the 114 Group 2 drugs associated 
with dementia, only eight still had a HR >1 when exposure was 
defined as first prescription ≥10 years before dementia diag-
nosis: dantron (used as a laxative in palliative care), nitrazepam, 
acamprosate (used in alcohol dependence), and five anticonvul-
sants (carbamazepine, phenytoin, sodium valproate, lamotrigine 
and primidone).
Of the four vaccines associated with a lower dementia risk, 
HRs were attenuated when only participants first prescribed 
them ≥5 and ≥10 years before dementia diagnosis were consid-
ered exposed.
There was variability in whether the HRs remained similar 
when only Alzheimer’s disease subtype codes were used to 
define the outcome (figure 3). From the Group 2 medications 
that were associated with dementia, 107/114 (93.9%) still had 
HRs >1 when Alzheimer’s disease was the outcome.
DISCUSSION
We conducted a hypothesis- generating medication- wide associa-
tion study, which found many medications to be associated with 
dementia, even after strict correction for multiple testing. The 
vast majority of these were associated with a higher dementia 
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prescribed >5 and>10 years before dementia diagnosis were 
included.
Medications associated with a lower dementia incidence
The four medications associated with a lower dementia inci-
dence were all vaccines: hepatitis A, typhoid, hepatitis A and 
typhoid combined, and diphtheria. Previous studies of vaccines 
and dementia risk have led to hypotheses that immunolog-
ical changes, modified by vaccination, may protect against 
dementia.17–19 However, the vaccines associated with a lower 
dementia incidence in our study were all travel vaccines, with 
similar HRs to several antimalarial drugs. This suggests that 
the observed association may be due to foreign travel, rather 
than a direct effect of the vaccines. The association could be 
due to reverse causation (ie, people with subclinical dementia 
pathology are less likely to travel), confounding by education or 
residual confounding by socioeconomic status.
Medications associated with a higher dementia incidence
Many drugs were associated with a higher dementia incidence. 
As expected, many Group 1 medications were associated with 
dementia. Rather than exclude these medications from the 
analysis, we included all prescription medications in case they 
revealed unexpected and potentially informative findings. One 
example of this is lithium, a drug usually prescribed for mania 
and/or bipolar affective disorder, which had a high HR (3.59), 
possibly reflecting an association between bipolar affective 
disorder and dementia.20
Other medications associated with dementia appeared to 
group around certain indications, such as gastro- oesophageal 
reflux disease, altered bowel habit, lower urinary tract symp-
toms, anxiety, sleep disturbance, pain and vertigo/nausea. HRs 
were often similar among drugs for the same indication, even if 
the mechanisms of action were different.
Reverse causation
Alzheimer’s disease and most other dementias are believed to have 
a long pre- clinical period, during which pathology accumulates 
before symptoms become apparent.21 22 This makes epidemio-
logical studies of dementia prone to reverse causality, meaning 
subclinical dementia is causing the association with a given ‘risk 
factor’. Several studies have revealed changes in the magnitude 
or direction of associations between particular risk factors and 
dementia with differing follow- up times.23–25 To explore this 
issue, we conducted a sensitivity analysis in which we excluded 
drugs prescribed for the first time <5 and <10 years before a 
dementia diagnosis. Almost all HRs fell during this sensitivity 
analysis, with very few drugs first prescribed ≥10 years before 
diagnosis still being associated with a higher dementia incidence.
Hypotheses
There are multiple potential interpretations for why some medi-
cations may be associated with dementia. We have made the full 
results publicly available in the hope that other researchers will 
use the outputs from this study to generate their own hypotheses 
before exploring them in external datasets.
Reverse causality is one plausible interpretation for many of 
the observed associations. The clustering of many of these drugs 
around certain indications, such as gastro- oesophageal reflux 
disease, altered bowel habit, lower urinary tract symptoms, 
anxiety, sleep disturbance, pain and vertigo or nausea, suggests 
that these symptoms are common in the years before dementia 
diagnosis. This raises the possibility of a non- cognitive syndrome 
in dementia, akin to that seen with the non- motor symptoms of 
Parkinson’s disease.26
Strengths and limitations
This study benefits from a systematic approach, allowing us to 
identify novel associations, compare drugs with similar indica-
tions but different mechanisms of action, and avoid selective 
reporting and publication bias. By using a population- based 
cohort we have maximised the generalisability of our findings 
to the wider population. The long follow- up times available for 
some individuals allowed us to conduct sensitivity analyses to 
explore the possibility of reverse causation.
Figure 3 Sensitivity analyses. (A) Exclusion of drugs prescribed <5 years before dementia diagnosis, (B) exclusion of drugs prescribed <10 years 
before dementia diagnosis, (C) Alzheimer’s disease (AD) subtype cases only (compared with all- cause dementia). Log hazard ratio (log HR) from the 
sensitivity analysis plotted against the original log HR from the full dataset. Each coloured marker represents a medication that was found to be 
associated with dementia. Each colour reflects a different British National Formulary chapter and section. Where markers remain on the diagonal 
line, the log HR in the sensitivity analysis is the same as in the original analysis. If the markers are below the diagonal line, the log HR is lower in the 
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There are several limitations. By defining participants as 
‘exposed’ to a medication if they were prescribed the drug at 
least once, we will have misclassified some participants as being 
exposed when they may never have taken the drug. We could 
have created an algorithm that included multiple prescriptions to 
minimise this risk, but this would have excluded single- use medi-
cations such as vaccines. Similarly, we did not investigate dose–
response relationships, as this would be too complex for the 
number of drugs studied. We anticipate that researchers seeking 
to further investigate some of these findings will wish to explore 
the role of single versus multiple prescriptions and include 
dose–response analyses in future studies. We only adjusted for a 
limited number of potential confounders. For example, level of 
education is not available within UK routinely- collected health-
care data, so we could not adjust for this. Routinely- collected 
healthcare data do not identify dementia with perfect accu-
racy. Although the positive predictive value (the proportion of 
people with a dementia code who do have dementia) of using 
these datasets to identify dementia cases is generally high,16 the 
sensitivity (proportion of true dementia cases identified as such) 
is not known.27 However, there is evidence that people with 
dementia who are identified in routinely- collected data as such 
may systematically differ from those not identified, suggesting 
the potential for ascertainment bias.28 It is likely that patients 
who were prescribed certain medications were more likely to 
interact with various healthcare services, which could in turn 
have made them more likely to be subsequently diagnosed with 
dementia. For the primary analysis we used ‘all- cause dementia’ 
as an outcome, which encompasses different diseases. We chose 
this because the accuracy of subtype dementia codes is known 
to be lower,16 and in older age many dementias are of ‘mixed’ 
pathology.29 Lastly, this study can only be hypothesis- generating, 
and further studies are required to investigate interesting associ-
ations in detail.
CONCLUSION
Many prescription medications are associated with a higher 
dementia incidence. The clustering of some drugs around 
certain indications may provide insights into the early stages 
of dementia. We encourage researchers to use these results to 
generate hypotheses for testing in external datasets.
What is already known on this subject
 ► Understanding and addressing modifiable risk factors is 
crucial for reducing dementia incidence. Previous studies 
have suggested that some medications may influence 
dementia risk. However, these associations have not been 
studied systematically.
What this study adds
 ► We found that almost a third of medications were associated 
with dementia. Drugs with differing mechanisms of action 
but the same indication appeared to have similar effect sizes, 
suggesting that many associations may be due to reverse 
causation as opposed to a direct causal effect. We have made 
our results publicly available with the intention that others 
may generate their own hypotheses based on these results.
Twitter Tim Wilkinson @tim_neuro
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